Scientists Identify a B-Cell Marker That May Play a Role in Type 1 Diabetes

Type 1 diabetes develops when the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas. B cells—white blood cells that produce antibodies—play an important role in this autoimmune attack. To better understand how B cells contribute to Type 1 diabetes, researchers analyzed genetic data from people with the disease and compared it to data from people without it.

The team used advanced computational methods to identify genes and proteins that appeared abnormal in Type 1 diabetes B cells. Four genes stood out, but one—CD180—showed the strongest connection to the immune changes driving the disease. CD180 is a protein that sits on the surface of B cells and helps them communicate and respond to signals.

When researchers examined individual B cells, they found that cells with high CD180 expression were more likely to be in an inflammatory state. These activated B cells also showed signs of being better at presenting antigens—essentially "waving a flag" that tells other immune cells to attack. This is a hallmark of the B-cell dysfunction seen in Type 1 diabetes.

The findings suggest that CD180 may be a useful marker for identifying which B cells are most likely to participate in the autoimmune attack. However, identifying a marker is different from understanding exactly how it drives disease or how to stop it. Much more research is needed to determine CD180's full role.

The researchers also investigated whether chlorogenic acid (CGA)—a compound found naturally in coffee, tea, and other plants—might modulate B-cell behavior. Using computer simulations and laboratory experiments, they explored whether CGA could interact with CD180 and affect how B cells respond to inflammatory signals.

In cell culture experiments, exposing B cells to chlorogenic acid during inflammatory stimulation appeared to reduce their activation. However, this was an exploratory laboratory study. Results in a petri dish do not automatically translate to effects in living people, and the researchers did not test whether CGA reduced the B cells' ability to attack insulin-producing cells.

This study adds to our growing understanding of which immune cells and molecular markers are involved in Type 1 diabetes development. By identifying CD180 as a key player, researchers have a new target to investigate. Future work might focus on whether blocking or modulating CD180 could slow or prevent the autoimmune attack.

The exploration of chlorogenic acid is preliminary and would require much more investigation—including animal studies and eventually human clinical trials—before any conclusions about its potential benefit could be drawn. For now, the study underscores how basic research on immune mechanisms can open new doors for understanding and potentially treating Type 1 diabetes.

Source: International journal of molecular sciences. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.